Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PR55α RNAi
- Development stage
- Preclinical
- Lead developer
- University of Nebraska Medical Center
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
PR55α RNAi refers to an experimental RNA interference-based therapeutic approach designed to silence the expression of PR55α, a regulatory subunit of the Protein Phosphatase 2A (PP2A) holoenzyme. Research, primarily conducted at the University of Nebraska Medical Center, has identified PR55α as a key promoter of pancreatic tumorigenesis, where it is significantly overexpressed and correlates with poor patient survival. By utilizing RNAi to deplete PR55α levels, this strategy aims to inhibit multiple oncogenic signaling pathways, including AKT, ERK1/2, and Wnt/β-catenin. In preclinical models of pancreatic ductal adenocarcinoma, PR55α depletion has been shown to significantly impair cell growth, clonogenicity, and mobility, while reducing tumorigenicity and distant metastasis in vivo.
- Other names
- PR55-alpha RNAiPR-55-alpha RNAiPR 55-alpha RNAiPPP2R2A RNAiPPP-2R2A RNAiPPP 2R2A RNAiPR55alpha RNAiPR-55alpha RNAiPR 55alpha RNAi
02
Targets
PPP2R2A (PP2A regulatory subunit B55 alpha)PP2A-B55α (Protein phosphatase 2A holoenzyme containing PR55α subunit)
Beyond the preview
Go deeper on PR55α RNAi.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PR55α RNAi.